JP2007500694A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007500694A5 JP2007500694A5 JP2006521803A JP2006521803A JP2007500694A5 JP 2007500694 A5 JP2007500694 A5 JP 2007500694A5 JP 2006521803 A JP2006521803 A JP 2006521803A JP 2006521803 A JP2006521803 A JP 2006521803A JP 2007500694 A5 JP2007500694 A5 JP 2007500694A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- phenyl
- heteroaryl
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 209
- 125000001072 heteroaryl group Chemical group 0.000 claims description 48
- -1 R 13 Chemical compound 0.000 claims description 43
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 43
- 125000003545 alkoxy group Chemical group 0.000 claims description 33
- 229910052739 hydrogen Inorganic materials 0.000 claims description 27
- 150000001875 compounds Chemical class 0.000 claims description 21
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 18
- 125000000623 heterocyclic group Chemical group 0.000 claims description 17
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 15
- 229910052717 sulfur Inorganic materials 0.000 claims description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 14
- 125000004414 alkyl thio group Chemical group 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 9
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 9
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 239000012453 solvate Substances 0.000 claims description 6
- 125000004434 sulfur atom Chemical group 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 3
- 125000004104 aryloxy group Chemical group 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 2
- 101100294110 Caenorhabditis elegans nhr-43 gene Proteins 0.000 claims description 2
- 101100294112 Caenorhabditis elegans nhr-47 gene Proteins 0.000 claims description 2
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 13
- 239000002904 solvent Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 claims 3
- 230000008878 coupling Effects 0.000 claims 2
- 238000010168 coupling process Methods 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000009835 boiling Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 235000009518 sodium iodide Nutrition 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 description 24
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- 0 CC(CC(*)N1C2CC(C)CC1*2)I Chemical compound CC(CC(*)N1C2CC(C)CC1*2)I 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0302155A SE0302155D0 (sv) | 2003-07-31 | 2003-07-31 | Chemical compounds |
| SE0401420A SE0401420D0 (sv) | 2004-06-03 | 2004-06-03 | Chemical compounds |
| PCT/SE2004/001149 WO2005009959A1 (en) | 2003-07-31 | 2004-07-26 | Piperidine derivatives as ccr5 receptor modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007500694A JP2007500694A (ja) | 2007-01-18 |
| JP2007500694A5 true JP2007500694A5 (enExample) | 2007-08-30 |
Family
ID=34107042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006521803A Pending JP2007500694A (ja) | 2003-07-31 | 2004-07-26 | Ｃｃｒ５受容体モジュレーターとしてのピペリジン誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20070112022A1 (enExample) |
| EP (1) | EP1654229B1 (enExample) |
| JP (1) | JP2007500694A (enExample) |
| AR (1) | AR045183A1 (enExample) |
| AT (1) | ATE361911T1 (enExample) |
| DE (1) | DE602004006424T2 (enExample) |
| ES (1) | ES2285485T3 (enExample) |
| TW (1) | TW200510307A (enExample) |
| UY (1) | UY28447A1 (enExample) |
| WO (1) | WO2005009959A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE529056C2 (sv) | 2005-07-08 | 2007-04-17 | Plasma Surgical Invest Ltd | Plasmaalstrande anordning, plasmakirurgisk anordning och användning av en plasmakirurgisk anordning |
| SE529053C2 (sv) | 2005-07-08 | 2007-04-17 | Plasma Surgical Invest Ltd | Plasmaalstrande anordning, plasmakirurgisk anordning och användning av en plasmakirurgisk anordning |
| SE529058C2 (sv) | 2005-07-08 | 2007-04-17 | Plasma Surgical Invest Ltd | Plasmaalstrande anordning, plasmakirurgisk anordning, användning av en plasmakirurgisk anordning och förfarande för att bilda ett plasma |
| CN101516884A (zh) | 2006-09-18 | 2009-08-26 | 弗·哈夫曼-拉罗切有限公司 | 八氢吡咯并[3,4-c]吡咯衍生物和它们作为抗病毒药的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20001420A1 (es) * | 1998-12-23 | 2000-12-18 | Pfizer | Moduladores de ccr5 |
| US6432981B1 (en) * | 1999-06-11 | 2002-08-13 | Merck & Co., Inc. | Cyclopentyl modulators of chemokine receptor activity |
| SE0103818D0 (sv) * | 2001-11-15 | 2001-11-15 | Astrazeneca Ab | Chemical compounds |
| SE0103819D0 (sv) * | 2001-11-15 | 2001-11-15 | Astrazeneca Ab | Chemical compounds |
| GB0127547D0 (en) * | 2001-11-16 | 2002-01-09 | Astrazeneca Ab | Chemical compounds |
| AR042628A1 (es) * | 2002-12-20 | 2005-06-29 | Astrazeneca Ab | Derivados de piperidina como moduladores del receptor ccr5 |
-
2004
- 2004-07-26 JP JP2006521803A patent/JP2007500694A/ja active Pending
- 2004-07-26 DE DE602004006424T patent/DE602004006424T2/de not_active Expired - Fee Related
- 2004-07-26 ES ES04749185T patent/ES2285485T3/es not_active Expired - Lifetime
- 2004-07-26 AT AT04749185T patent/ATE361911T1/de not_active IP Right Cessation
- 2004-07-26 EP EP04749185A patent/EP1654229B1/en not_active Expired - Lifetime
- 2004-07-26 WO PCT/SE2004/001149 patent/WO2005009959A1/en not_active Ceased
- 2004-07-26 US US10/566,799 patent/US20070112022A1/en not_active Abandoned
- 2004-07-27 TW TW093122417A patent/TW200510307A/zh unknown
- 2004-07-30 AR ARP040102732A patent/AR045183A1/es unknown
- 2004-07-30 UY UY28447A patent/UY28447A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2609803T3 (es) | Nuevos derivados de triazol antifúngicos | |
| EP2401265B1 (en) | Derivatives of 1-pyri(mid)in-2-yl-pyrazole-4-carboxylic acid which are useful for therapy or prophylaxis of cardiovascular diseases | |
| AU2004213616B2 (en) | A process of preparing imatinib | |
| JP7787063B2 (ja) | オーロラキナーゼ阻害剤およびその使用 | |
| RU2581834C1 (ru) | Новое пиперидиновое соединение или его соль | |
| CA2529686C (en) | 2-acylaminothiazole derivative or salt thereof | |
| BR112015004192B1 (pt) | sulfamoíl-arilamidas, composição farmacêutica que os compreende e uso das mesmas no tratamento da hepatite b | |
| ES2334517T3 (es) | Derivados de triazol sustituidos como antagonistas de oxitocina. | |
| RU2004122114A (ru) | Химические соединения | |
| JP2010513322A5 (enExample) | ||
| BR112017016193B1 (pt) | Derivados de 4h-pirrolo[3,2-c]piridin-4-ona | |
| JPWO2021081212A5 (enExample) | ||
| US20250145589A1 (en) | Pyridine derivative and use thereof | |
| RU2004104625A (ru) | Аналоги простагландинов в качестве агонистов рецептора ep4 | |
| RU95118133A (ru) | Гетероциклические соединения, способы их получения и фармацевтическая композиция | |
| WO2003000660A1 (fr) | Derive de quinoleine et derive de quinoleine permettant d'inhiber l'auto-phosphorylation du recepteur des proliferateurs des hepatocytes, ainsi que des compositions medicinales contenant ce derive | |
| JP2005525341A5 (enExample) | ||
| JP2006522037A5 (enExample) | ||
| BR112020027064A2 (pt) | derivados de quinazolina do tipo éter biarílico | |
| CN105916506B (zh) | 作为tam家族激酶抑制剂的喹唑啉衍生物 | |
| JP2008503573A5 (enExample) | ||
| JP2020511482A (ja) | 新規なピロロピリジン誘導体、その製造方法及び用途 | |
| CN107922345B (zh) | 作为碳酸酐酶抑制剂的芳基磺酰胺化合物及其治疗用途 | |
| WO2006003881A1 (ja) | 新規なアリールアミジン誘導体およびその塩ならびにそれらを含有する抗真菌剤 | |
| US20190202826A1 (en) | Phosphotidylinositol 3-Kinase Inhibitors |